Maybe mAb therapeutics will someday be the answer to treating Alzheimer’s disease, but respondents to a recent GEN poll are yet to be convinced. A majority of respondents (52.4%) said they did not see that happening, compared with 28.6% that did.
With the global market for neurodegenerative treatments expected to exceed $43.4 billion by 2015, according to Global Industry Analysts, companies are pursuing biologics like mAb therapeutics as drug candidates for Alzheimer and other neurodegenerative disorders and moving away from small molecule drugs and peptides, following early- and late-stage drug failures. However, few to no drugs have emerged that impact either the cause or progression of diseases of the central nervous system.